Trial Profile
A Global Enhanced Pharmacovigilance Pregnancy Surveillance Study of Pregnant Women Exposed to Yervoy With 5 -Year Pediatric Follow-up
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 16 Mar 2022 Planned End Date changed from 31 Aug 2024 to 5 Feb 2021.
- 16 Mar 2022 Planned primary completion date changed from 31 Aug 2024 to 5 Feb 2021.
- 16 Mar 2022 Status changed from recruiting to withdrawn prior to enrolment.